Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736349 | 0.80 | CHRNA7 (0.34) | ESR1ESR2 | |
| SCHEMBL20718221 | 0.78 | KMT2A (0.38) | LMNAMEN1KMT2AHRH1MAPT | |
| SCHEMBL24810714 | 0.77 | LMNA (0.41) | LMNAMEN1KMT2AESR1ESR2 | |
| SCHEMBL179333 | 0.77 | LMNA (0.50) | LMNAMEN1KMT2AHRH1NPC1 | |
| SCHEMBL20037983 | 0.76 | LMNA (0.37) | LMNAMEN1KMT2AESR1HRH1 | |
| SCHEMBL20389049 | 0.76 | KMT2A (0.37) | LMNAMEN1KMT2AHRH1MAPT | |
| SCHEMBL828068 | 0.76 | GABRP (0.40) | LMNAMEN1KMT2AESR1ESR2 | |
| SCHEMBL18661804 | 0.75 | SLC2A1 (0.39) | LMNAMEN1KMT2AHRH1MAPT | |
| SCHEMBL20143958 | 0.74 | LMNA (0.40) | LMNAMEN1KMT2AHRH1SMN1; SMN2 | |
| SCHEMBL18927429 | 0.74 | KMT2A (0.40) | LMNAMEN1KMT2AHRH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169654-A1 | New Organic Compounds | SERVIER PHARMACEUTICALS LLC (US) | 2022-06-02 | — | — | US | disclosed |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | DAPK1, ATF1, BAD | LMNA 1311/4885MEN1 4337/4885KMT2A 3916/4885 |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | DAPK1, ATF1, BAD | LMNA 1311/4885MEN1 4337/4885KMT2A 3916/4885 |
| US-20220169654-A1 | New Organic Compounds | MNAT1, MAT2A, EIF4A2 | LMNA 1352/4885MEN1 851/4885KMT2A 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.